Welcome to Chemren.com!Help Center 中文 Sign upLogin
Post Information
Products Suppliers Technologies Group Buying Surplus
Organic Raw Materials
Hydrocarbon Compounds Alcohols、Phenols、Ethers Aldehydes、Ketones、Quinones Esters Carboxylic Acids Halides Aromatic Compounds Heterocyclic Compounds Amino Acids、Proteins、Nucleic Acids Nitrogenous Organic Compounds Nitrogenous Organic Compounds Phosphorated Organic Compounds Sulfurated Organic Compounds Other Elemental Organic Compounds Organic Salts Carbohydrates Others
Organic Intermediates
Synthetic Intermediates Other Intermediates
Biochemicals and Pharmaceutical Chemicals
APIs Pharmaceutical Intermediates Biological Products Pharmaceutical Excipients Veterinary Drugs Finished Dosage Forms Pharmaceutical Impurities
Pesticides Fertilizers Pesticide Intermediates Others
Food and Feed Additives
Food Additives Feed Additives
Flavors and Fragrances
Flavors and Essences Spices Flavor and Fragrance Intermediates
Dyes and Pigments
Dyes Pigments Dye Intermediates
Catalysts and Additives
Additives and Auxiliaries Catalysts
Coatings and Paints
Coatings Paints Inks Others
Organic Adhesives Inorganic Adhesives
Inorganic Chemicals
Inorganic Salts Inorganic Acids Inorganic Alkalines Inorganic Oxides Elements Halides Others
Natural Products and Extracts
Plant Extracts Herbal Extracts Natural Products
Material Chemicals
Polymer Materials Metal and Ceramic Materials Nanomaterials
Electronic Chemicals
OFET Materials Electrode Materials Liquid Crystals
Household Chemicals
Cosmetics Oral Care Chemicals Skin Care Chemicals Household Insecticides Detergent Chemicals
Heat Exchange Equipment Reaction Equipment Crushing Equipment Mixing Equipment Separation Equipment Pressure Vessel Refrigeration Equipment Mass Transfer Equipment Molding Equipment Storage/Transport Equipment Drying Equipment Green Facilities Pump/Valve Equipment Conveying Equipment Instrumentation Auxiliary Equipment Crystallization Equipment Seal Machinery Heating Equipment Other Chemical Equipment
Other Chemicals
Other Chemicals
Location:Home > News Detail

This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX

Last Update:2019-04-15   |   Comments:0 A+ A-

Brief:A storied Chinese pharma player is aiming for a second shot at joining some pre-revenue biotechs on the Hong Kong Stock Exchange, in an IPO that could fetch anywhere between $500 million and $1 billion.


Huijuan Zhong

A storied Chinese pharma player is aiming for a second shot at joining some pre-revenue biotechs on the Hong Kong Stock Exchange, in an IPO that could fetch anywhere between $500 million and $1 billion.


Hansoh Pharmaceutical Group re-filed its application after first laying out its pitch last September. While it had initially pencilled in $1 billion, a source is now telling Reuters that the new range will be $500 million to $800 million — while another indicated $800 million to $1 billion.


A storied company running a profitable innovative and generic drug business in China, Hansoh booked a revenue of $1.15 billion (RMB 7.72 billion) last year, almost half of which was from oncology products, translating to $283 million in profit.


Other key therapeutic areas include the central nervous system, anti-infectives, diabetes, gastrointestinal and cardiovascular.


The company did not explain why its first IPO attempt didn’t go through, but disclosed that Boyu Capital joined Hillhouse as a big institutional investor this January, committing around $248 million for a 3% stake. According to the filing, the corresponding valuation was almost $8.3 billion.


Huijuan Zhong, founder and chairlady of the group, retains control of the company through an indirectly held stake that registers at more than 75% even after the transaction. Zhong is one half of a power couple towering over China’s pharma industry: Her husband, Piaoyang Sun, is the head of Jiangsu Hengrui Medicine, internationally known for a PD-1 drug Incyte paid millions to partner with.


Cen Junda of Apex Medical claims 19%, while Hillhouse Capital is in for less than 3% based on a 2016 cash infusion.


While first-to-market generics — including copycat versions of the antipsychotic olanzapine and chemotherapy drug pemetrexed — will remain a core focus for Hansoh as a public company, it also has an ambitious plan for the novel compounds in its giant pipeline, which totals “nearly 100 drug candidates.”


In its application, Hansoh spotlighted four of these among the 30 assets it’s looking to launch between now and 2020: HS-10296, an EGFR tyrosine kinase inhibitor for non-small cell lung cancer; flumatinib mesylate, which attempts to treat chronic myelogenous leukemia by targeting the Bcr-Abl gene; hepatitis B drug HS-10234; and a long-acting GLP-1 therapy dubbed polyethylene glycol loxenatide.

About Us
Contact Us
User Agreement
Privacy Policy
Resource Docking
Offline Activities
Technical Services
Sales Promotion
Update Info
Retrieve Password
Sign Up
User Center
Product Presales
Technology Purchase
Technology Transfer
Sell Products